Akebia Therapeutics, Inc. (NASDAQ: AKBA) and ​Vifor Pharma Group today announced they have entered into an exclusive license agreement ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Private Equity

Akebia Therapeutics (AKBA) PT Raised to $21 at Needham & CompanyMay 16, 2017 11:19 AM Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA ApprovalMay 16, 2017 1:00 AM Akebia Therapeutics (AKBA), Vifor Pharma Enter Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care; Deal Includes $50M Equity InvestmentMay 15, 2017 4:06 PM